Evaluating the benefits of glycoprotein IIb/IIIa inhibitors in heart failure at baseline in acute coronary syndromes

American Heart Journal

Volumn 147, Issue 1, 2004, Pages 84-90

  Srichai, Monvadi B ^a   Jaber, Wael A ^a   Prior, David L ^b   Marso, Steven P ^c   Houghtaling, Penny L ^a   Menon, Venu ^d   Simoons, Maarten L ^e   Harrington, Robert A ^f   Hochman, Judith S ^d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b ST VINCENT S HOSPITAL   (Australia)

^c SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^d ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; HEPARIN; PLACEBO; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; COMPARATIVE STUDY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOUBLE BLIND PROCEDURE; FATALITY; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORALITY; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0346786489     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00530-1     Document Type: Article

References (34)

1. Bahit MC, Shah MR, Granger CB. Prognostic significance of manifestations of acute congestive heart failure: results from GUSTO IIb. J Am Coll Cardiol 2000;35:213.
2. Killip T III, Kimball JT. Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. Am J Cardiol 1967;20:457-64.
3. Stevenson RN, Wilkinson P, Marchant BG, et al. Relative value of clinical variables, treadmill stress testing, and Holter ST monitoring for postinfarction risk stratification. Am J Cardiol 1994;74:221-5.
4. Jacobs DR Jr, Kroenke C, Crow R, et al. PREDICT: a simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: the Minnesota heart survey. Circulation 1999;100:599-607.
5. Vaur L, Danchin N, Genes N, et al. Epidemiology of myocardial infarction in France: therapeutic and prognostic implications of heart failure during the acute phase. Am Heart J 1999;137:49-58.
6. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-77.
7. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-8.
8. Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-6.
9. Cleland JG, Erhardt L, Murray G, et al. Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure: a report from the AIRE Study Investigators. Eur Heart J 1997;18:41-51.
10. Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 1999;341:625-34.
11. Hochman JS, Jaber WA, Bates ER. Angioplasty versus thrombolytics for patients presenting with congestive heart failure; GUSTO-IIb substudy findings. J Am Coll Cardiol 1998;31:210A.
12. Hasdai D, Topol EJ, Califf RM, et al. Cardiogenic shock complicating acute coronary syndromes. Lancet 2000;356:749-56.
13. Hasdai D, Harrington RA, Hochman JS, et al. Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. J Am Coll Cardiol 2000;36:685-92.
14. Lewis HD Jr, Davis JW, Archibald DG, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration cooperative study. N Engl J Med 1983;309:396-403.
15. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988;319:1105-11.
16. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation 1998;97:2386-95.
17. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-82.
18. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2000;36:970-1062.
19. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysls of all major randomised clinical trials. Lancet 2002;359:189-98.
20. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436-43.
21. Boersma E, Pieper KS, Steyerberg EW, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000;101:2557-67.
22. Wellford L, Ashcom TL, Whitney EJ, et al. Changing presentation of coronary heart disease in an inpatient population within the U.S. military health care system. Mil Med 1993;158:598-603.
23. McGovern PG, Jacobs DR Jr, Shahar E, et al. Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota heart survey. Circulation 2001;104:19-24.
24. Spencer FA, Meyer TE, Gore JM, et al. Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure: the National Registry of Myocardial Infarction. Circulation 2002;105:2605-10.
25. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985;71:699-708.
26. Richardson PD, Davies MJ, Born GV. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 1989;2:941-4.
27. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992;326:242-50.
28. Davies MJ, Bland JM, Hangartner JR, et al. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death. Eur Heart J 1989;10:203-8.
29. Stone PH, Raabe DS, Jaffe AS, et al. Prognostic significance of location and type of myocardial infarction: independent adverse outcome associated with anterior location. J Am Coll Cardiol 1988;11:453-63.
30. Matetzky S, Barabash GI, Rabinowitz B, et al. Q wave and Non-Q wave myocardial infarction after thrombolysis. J Am Coll Cardiol 1995;26:1445-51.
31. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. J Am Coll Cardiol 2001;38:2101-13.
32. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-90.
33. Shah MR, Bahit MC, Granger CB. Clinical features of patients with heart failure after an acute coronary syndrome: findings from GUSTO-IIb. J Am Coll Cardiol 2000;35:212.
34. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.